Denali Therapeutics Inc. DNLI Total debt

Total debt at other companies

Eli LillyLLY

$54.91B+37.6%

Regeneron PharmaceuticalsREGN

$2.71B+0.1%

uniQureQURE

$62.83M-5.8%

PTC TherapeuticsPTCT

$395.09M+0.1%

Viridian Therapeutics, Inc.VRDN

$114.36M+395%

Eton Pharmaceuticals, Inc.ETON

$31.26M+3.7%

FAQ

What is Denali Therapeutics Inc.'s total debt?

Denali Therapeutics Inc. (DNLI) reported total debt of $37.69M in Q2 2026.

How has Denali Therapeutics Inc.'s total debt changed year-over-year?

Denali Therapeutics Inc.'s total debt decreased by 21.4% year-over-year, from $47.97M to $37.69M.

What is the long-term trend for Denali Therapeutics Inc.'s total debt?

Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s total debt has grown at a -9.3% compound annual growth rate (CAGR), from $68.87M to $42.37M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.